The rapid advancement of artificial intelligence (AI) technology has ushered in an era of unprecedented innovation and potential. As AI continues to permeate various sectors, including healthcare, finance, and manufacturing, regulatory bodies worldwide are grappling with the challenge of establishing robust frameworks to govern its development and deployment.
This comprehensive overview of the current regulatory landscape surrounding AI has been written following Dr Peter Gough’s presentation at the 2nd NSF Pharma biotech conference in London on November 14th, 2024, at The Royal Society of Chemistry in London, UK. The article and presentation both focus on recent developments in the European Union and the United States.
As AI systems become increasingly sophisticated, concerns about their potential impact on society, privacy, and human autonomy have grown. Regulatory authorities are tasked with striking a delicate balance between fostering innovation and safeguarding public interests. This update aims to shed light on the latest regulatory initiatives, emerging guidelines, and industry best practices that are shaping the future of AI governance.
Click here to read more about artificial intelligence and pharma
